Research ArticleArticle
Rituximab in the Treatment of Jo1 Antibody–associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response
Jutta Bauhammer, Norbert Blank, Regina Max, Hanns-Martin Lorenz, Ulrich Wagner, Dietmar Krause and Christoph Fiehn
The Journal of Rheumatology June 2016, jrheum.150844; DOI: https://doi.org/10.3899/jrheum.150844
Jutta Bauhammer
From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany. C. Fiehn and H.M. Lorenz have received speaking honoraria from Roche. J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases. Address correspondence to Prof. C. Fiehn, ACURA Centre for Rheumatic Diseases, Rotenbachtalstr. 5, 76530 Baden-Baden, Germany. E-mail: c.fiehn@acura-kliniken.com. Accepted for publication April 20, 2016.
Norbert Blank
From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany. C. Fiehn and H.M. Lorenz have received speaking honoraria from Roche. J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases. Address correspondence to Prof. C. Fiehn, ACURA Centre for Rheumatic Diseases, Rotenbachtalstr. 5, 76530 Baden-Baden, Germany. E-mail: c.fiehn@acura-kliniken.com. Accepted for publication April 20, 2016.
Regina Max
From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany. C. Fiehn and H.M. Lorenz have received speaking honoraria from Roche. J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases. Address correspondence to Prof. C. Fiehn, ACURA Centre for Rheumatic Diseases, Rotenbachtalstr. 5, 76530 Baden-Baden, Germany. E-mail: c.fiehn@acura-kliniken.com. Accepted for publication April 20, 2016.
Hanns-Martin Lorenz
From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany. C. Fiehn and H.M. Lorenz have received speaking honoraria from Roche. J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases. Address correspondence to Prof. C. Fiehn, ACURA Centre for Rheumatic Diseases, Rotenbachtalstr. 5, 76530 Baden-Baden, Germany. E-mail: c.fiehn@acura-kliniken.com. Accepted for publication April 20, 2016.
Ulrich Wagner
From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany. C. Fiehn and H.M. Lorenz have received speaking honoraria from Roche. J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases. Address correspondence to Prof. C. Fiehn, ACURA Centre for Rheumatic Diseases, Rotenbachtalstr. 5, 76530 Baden-Baden, Germany. E-mail: c.fiehn@acura-kliniken.com. Accepted for publication April 20, 2016.
Dietmar Krause
From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany. C. Fiehn and H.M. Lorenz have received speaking honoraria from Roche. J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases. Address correspondence to Prof. C. Fiehn, ACURA Centre for Rheumatic Diseases, Rotenbachtalstr. 5, 76530 Baden-Baden, Germany. E-mail: c.fiehn@acura-kliniken.com. Accepted for publication April 20, 2016.
Christoph Fiehn
From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany. C. Fiehn and H.M. Lorenz have received speaking honoraria from Roche. J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases. Address correspondence to Prof. C. Fiehn, ACURA Centre for Rheumatic Diseases, Rotenbachtalstr. 5, 76530 Baden-Baden, Germany. E-mail: c.fiehn@acura-kliniken.com. Accepted for publication April 20, 2016.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Rituximab in the Treatment of Jo1 Antibody–associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response
Jutta Bauhammer, Norbert Blank, Regina Max, Hanns-Martin Lorenz, Ulrich Wagner, Dietmar Krause, Christoph Fiehn
The Journal of Rheumatology Jun 2016, jrheum.150844; DOI: 10.3899/jrheum.150844
Rituximab in the Treatment of Jo1 Antibody–associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response
Jutta Bauhammer, Norbert Blank, Regina Max, Hanns-Martin Lorenz, Ulrich Wagner, Dietmar Krause, Christoph Fiehn
The Journal of Rheumatology Jun 2016, jrheum.150844; DOI: 10.3899/jrheum.150844